With a visit from then-President Donald Trump, FUJIFILM Diosynth Biotechnologies’ Innovation Center in Morrisville announced it would manufacture components for Novavax’s attempt at producing a COVID-19 vaccine. Eleven months later, clinical trials show it to be more than 90 percent effective.
David Wohl, MD, professor of medicine in the division of infectious diseases, discussed Novavax with CBS-17.
“This is where they actually take a virus and give it some genetic information, put it inside of the cells from a moth, like the insect, a moth – use that cell to act as sort of a crop to make spiked proteins, collect those spiked proteins, assemble them together and then inject it,” Wohl said.
Watch or read the CBS-17 report here.